Role of Fibrocytes in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Clinical Trial

— FIREBROB  

Official title:

Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01196832
• Other study ID #: CHUBX 2010/05
• Status: Completed
• Start date: March 11, 2011
• Est. completion date: May 31, 2016

Study information

• Verified date: February 2022
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling. Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation. Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 115
• Est. completion date: May 31, 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
• Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
• Written informed consent

Exclusion Criteria:

• Subject without any social security or health insurance
• Asthma, lung fibrosis or idiopathic pulmonary hypertension
• Chronic viral infections (hepatitis, HIV)

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Procedure:
• blood sample
blood sample for fibrocytes analysis
• Clinical and functional evaluation
Plethysmography, Carbon monoxide capacity of transfer , arterial gaz

Locations

Country	Name	City	State
France	CHU de Bordeaux	Pessac

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of circulating blood fibrocytes	Sampling of blood in Chronic obstructive pulmonary disease patients	Day 1
Primary	Number of circulating blood fibrocytes	Sampling of blood in Chronic obstructive pulmonary disease patients	2 months
Secondary	Characterization of fibrocytes	Sampling of blood	Day 1 and at 2 months
Secondary	Differenciation of blood fibrocytes	Sampling of blood	Day 1 and at 2 months
Secondary	Chemotactism of blood fibrocytes	Sampling of blood	Day 1 and at 2 months
Secondary	Number of exacerbation		12 months after V2
Secondary	Mortality		12 months after V2
Secondary	Annual decline of ventilatory function		12 months after V2